A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

Phase 3Not Yet RecruitingNCT07807995

Vertex Pharmaceuticals Incorporated605 enrolled

Overview

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

605

Conditions

Immunoglobulin A Nephropathy

Interventions

PovetaciceptDRUG

Subcutaneous injection administration.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Completed the Week 104 visit in the parent study VX24-AIS-D08 (NCT06564142) and has not permanently discontinued study drug * Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 15 milliliters per minute (mL/min)/1.73 square meter (m\^2) within 45 days of Day 1 of this study Key Exclusion Criteria: \- Planned participation in another interventional, therapeutic clinical trial (other than the parent study). Other protocol defined Inclusion/Exclusion criteria may apply.

Outcomes

Primary Outcomes

Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Time frame: From Day 1 up to Week 112